Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial

Key Points

• Nivolumab response is predicted by the presence of oligoclonal B cells and specific fusion genes, leading to better outcomes.
• A key predictive metric suggests that patients with oligoclonal B cells exhibit a 30% higher response rate.
• Observational analysis from a phase II trial evaluates patient outcomes to determine predictive biomarkers for treatment.
• Identifying these biomarkers may enable personalized approaches to therapy, but further studies are necessary for validation.